⚠️ Educational purposes only. PeptideIQ does not constitute medical advice, diagnosis, or treatment. Peptide therapy should only be pursued under the guidance of a licensed medical provider. Many peptides discussed are research-grade compounds not approved by the FDA. Always verify current legal status in your jurisdiction before use.
← Back to library
Tirzepatide
Tirzepatide (Mounjaro / Zepbound)
Strong RCTFDA Approved
A dual GLP-1/GIP receptor agonist showing even greater weight loss than semaglutide in head-to-head trials.
Mechanism of action
Dual GLP-1 and GIP receptor agonism, superior appetite suppression and insulin sensitization
Primary benefits
- ✓Up to 22% body weight reduction
- ✓Superior to semaglutide in trials
- ✓Blood sugar control
- ✓Reduced appetite
- ✓Improved lipid profile
Dosing
Beginner
2.5 mg/week (weeks 1-4)
Intermediate
5-10 mg/week
Advanced
15 mg/week (max dose)
Frequency: Once weekly
Timing: Same day each week
Route: Subcutaneous injection
Cycling protocol
Duration
16-20+ weeks
Pattern
Monthly titration
Break after
Ongoing under medical supervision
Important warnings
- ⚠️Prescription only
- ⚠️Compounded tirzepatide restricted March 2025
- ⚠️GI side effects during titration
- ⚠️Contraindicated with thyroid cancer history